Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + nivolumab + paclitaxel before surgery and nivolumab after surgery for primary triple-negative breast cancer
ACTRN12617000651381Phase 2Completed
- Sponsor
- Breast Cancer Trials
- Start
- Dec 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab and paclitaxel in triple-negative breast cancer (TNBC), sponsored by Breast Cancer Trials. Primary endpoint: Pathological complete response in breast and axilla. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ACTRN12617000651381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000651381.